Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNγ production

Henrique P. Lemosa, Renata Grespana, Silvio M. Vieiraa,b, Thiago M. Cunhaa, Waldiceu A. Verri, Jr.a, Karla S. S. Fernandesa, Fabricio O. Soutoa, Iain B. McNnese, Sergio H. Ferreiraa,1, Foo Y. Liewc,1, and Fernando Q. Cunhaa,1

aDepartment of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo 14.049-900, Brazil; bLaboratory of Pharmacology, National Institute for Research in the Amazon (INPA), Manaus, Amazonas 69060-001, Brazil; and cDivision of Immunology, Infection and Inflammation, Faculty of Medicine, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow G12 8TA, United Kingdom

Contributed by Sergio H. Ferreira, December 16, 2008 (sent for review November 13, 2008)

IL-23/IL-17-induced neutrophil recruitment plays a pivotal role in rheumatoid arthritis (RA). However, the mechanism of the neutrophil recruitment is obscure. Here we report that prostaglandin inhibits IL-23/IL-17-induced neutrophil migration in a murine model of RA by inhibiting IL-12 and IFNγ production. Methylation BSA (mBSA) and IL-23-induced neutrophil migration was inhibited by anti-IL-23 and anti-IL-17 antibodies, COX inhibitors, IL-12, or IFNγ but was enhanced by prostaglandin E2 (PGE2). IL-23-induced neutrophil migration was increased by PGE2 and suppressed by COX inhibition or IL-12. Furthermore, COX inhibition failed to reduce IL-23-induced neutrophil migration in IL-12- or IFNγ-deficient mice. IL-23/IL-17-induced neutrophil migration was not affected by COX inhibitors, IL-12, or IFNγ but was inhibited by MK886 (a leukotriene synthesis inhibitor), anti-TNFα, anti-CXCL1, and anti-CXCL5 antibodies and by repertaxin (a CXCR1/2 antagonist). These treatments all inhibited mBSA- or IL-23-induced neutrophil migration. IL-17 induced neutrophil chemotaxis through a CXCL chemokines-dependent pathway. Our results suggest that prostaglandin plays an important role in IL-23-induced neutrophil migration in arthritis by enhancing IL-17 synthesis and by inhibiting IL-12 and IFNγ production. We thus provide a mechanism for the pathogenic role of the IL-23/IL-17 axis in RA and also suggest an additional mechanism of action for nonsteroidal anti-inflammatory drugs.

Rheumatoid arthritis (RA) is a debilitating chronic autoimmune disease with repeated acute episodes characterized by infiltration of leukocytes, particularly neutrophils, into the synovial and periarticular tissues. The recruited neutrophils contribute to the development of hyperplasia of the synovial tissue, pannus formation, and subsequent cartilage and bone destruction (1–3).

Over the past decade, IL-12-driven T-helper (Th)-1 cells, characterized by IFNγ production, have been implicated in the development of RA (4). However, it was demonstrated recently that mice lacking other components of the IL-12/IFNγ pathway (IL-12p35−/−, IFNγ−/−, IFNγR−/−) are highly susceptible to collagen-induced arthritis (CIA), indicating that these cytokines are not always required for disease induction (5–7). These apparently contradictory findings coupled with the discovery of IL-23, a cytokine that shares a p40 subunit with IL-12 and is distinct from the IL-12/IFNγ pathway (8).

The current concept is that the combination of TGF-β and IL-6 induces the differentiation of Th0 cells to Th17 cells (9). IL-23 in conjunction with IL-1 then contributes to the expansion and maintenance of Th17 cells that, once activated, release the cytokines IL-17A, IL-17F, IL-22, TNFα, and IL-6, all of which can induce inflammatory responses (9–12). Consistent with this notion, it was shown that IL-23 gene-targeted mice did not develop clinical signs of CIA and were completely resistant to the development of joint and bone disease, despite normal Th1 cell activation (5). Moreover, mice lacking IL-17 are more resistant to CIA induction and IL-17 is essential for the previously recognized proinflammatory effect of IL-1 in arthritis (13, 14).

Clinically, synovial fluid of RA patients exhibits elevated numbers of IL-17-expressing cells and increased levels of cytokines IL-23 and IL-17 (15, 16).

Neutrophil migration induced by the IL-23/IL-17 axis has been implicated in the pathogenesis of RA (17). However, the precise mechanism how the IL-23/IL-17 axis induces neutrophil migration in the articular context is unknown. We have reported previously that intra-articular (tibiofemoral joint) injection of antigen (methylated BSA, mBSA) induced a significant neutrophil migration in the articular context is unknown. We have reported previously that intra-articular (tibiofemoral joint) injection of antigen (methylated BSA, mBSA) induced a significant neutrophil migration in the articular cavity in immunized mice compared with non-immunized mice (18). Lipid mediators such as prostaglandins, particularly prostaglandin E2 (PGE2), are commonly found in the synovial fluid of RA patients and clearly are involved in the tissue inflammation observed in these subjects (19, 20).

Therefore, we investigated the potential association of PGE2 and IL-23/IL-17 in the neutrophil recruitment observed in the antigen-induced arthritis (AIA). We report here that prostaglandin mediates IL-23/IL-17-induced neutrophil migration in AIA by enhancing IL-17 synthesis via the down-regulation of IL-12 and IFNγ production. Our study therefore provides a mechanism by which the IL-23/IL-17 axis induces neutrophil migration and hence pathogenesis of articular inflammation and also reveals a pathway of action of nonsteroidal anti-inflammatory drugs.

Results

The IL-23/IL-17 Axis Is Essential for the Neutrophil Migration in Antigen-Induced Arthritis. Intra-articular (tibiofemoral joint) injection of mBSA in mBSA-immunized mice induced a significant neutrophil migration to the articular cavity compared with non-immunized mice. The migration peaked 24 h after mBSA challenge (10 μg/articular cavity) (18). mBSA-induced neutrophil recruitment was significantly inhibited by anti-IL-23 or anti-IL-17 antibodies (Fig. 1A).

The authors declare no conflict of interest.


The authors declare no conflict of interest.

1To whom correspondence may be addressed. E-mail: shferrei@fmrp.usp.br, f.y.liew@clinmed.gla.ac.uk, or fdqcunha@fmrp.usp.br.

This article contains supporting information online at www.pnas.org/cgi/content/full/0812782106/DCSupplemental.

PNAS | April 7, 2009 | vol. 106 | no. 14 | 5954–5959

www.pnas.org/cgi/doi/10.1073/pnas.0812782106

Contributed by Sergio H. Ferreira, December 16, 2008 (sent for review November 13, 2008)
IL-23 and IL-17 were found in the knee joints 3 h after mBSA challenge (Fig. 1B). These results indicate a key role of IL-23 and IL-17 in neutrophil recruitment to the knee joints induced by specific antigen challenge.

Because the effector functions of IL-23 in the pathogenesis of RA depend on the induction of IL-17 production (21), we examined the role of IL-17 in IL-23-induced neutrophil migration. IL-23 induced a dose-dependent neutrophil migration after intra-articular injection compared with control (intra-articular injection of the vehicle, saline). The maximal response was observed with 10 ng/articular cavity 6 h after intra-articular injection of mBSA (10 μg/cavity) in immunized mice (C and D) Neutrophils harvested from articular cavity 6 h after intra-articular injection of IL-23 (1–10 ng/cavity, closed bars) or saline (Sal, open bar) in mice treated with a co-injection of IgG control (α-CTLu), anti-IL-23 (5 μg/cavity), or anti-IL-17 (10 μg/cavity) antibodies. *P < 0.05 vs. saline control group; **P < 0.05 vs. IL-23 or mBSA (immunized) groups. Data are mean ± SEM, n = 5, representative of 3 experiments.

IL-23-Induced Neutrophil Migration Is Prostanoid Dependent. Prostaglandins are found commonly in synovial fluid of RA patients and are clearly involved in the tissue inflammation observed in these individuals (19, 20). Thus, we investigated the potential role of prostaglandins in the neutrophil recruitment observed in AIA. Neutrophil migration induced by mBSA challenge in mBSA-immunized mice was markedly attenuated when the mice were treated with either indomethacin (a nonselective COX inhibitor), dose dependently, or etoricoxib (a COX-2 selective inhibitor) (Fig. 2A). Furthermore, IL-23-induced neutrophil migration to articular and peritoneal cavities also was inhibited by indomethacin (dose dependently) or etoricoxib (Figs. 2A and S1C). The effect of indomethacin was examined on another cytokine, IL-15, which has a significant role in the manifestation of RA and induces neutrophil migration and IL-17 production (22). However, indomethacin treatment did not affect the neutrophil migration induced by either IL-15 or N-formylmethionyl-leucyl-phenylalanine, a non-specific flogistic stimulus (data not shown), indicating that prostanoids are specifically involved in IL-23-induced neutrophil migration. Notably the range of indomethacin dose that inhibited mBSA- or IL-23-induced neutrophil migration corresponds to the range that inhibits prostanoid production in vivo (23). IL-23 also triggered a significant increase in COX-2 mRNA expression in peritoneal cells 30 min after IL-23 injection. The expression peaked at 1.5 h and returned to baseline levels after 3 h (Fig. 2B). Moreover, elevated levels of PGE2 were found in the knee joints 3 and 12 h after mBSA challenge (Fig. 2C) and in supernatants of cultured lymph node cells stimulated with IL-23 for 36 h (Fig. 2D).

PGE2 Enhances Neutrophil Migration by Inhibiting the IL-12/IFNγ Pathway. We then investigated the mechanisms by which prostanoids mediate IL-23-induced neutrophil migration. Intra-articular co-administration of low doses of mBSA (1 μg) or IL-23 (1 ng) with PGE2 induced a significant neutrophil migration into the knee joint at levels comparable to the maximal response to mBSA (10 μg) or IL-23 (10 ng) (Fig. 3A and B), suggesting that PGE2 can enhance the IL-23-induced neutrophil migration observed in AIA. Moreover, consistent with previous reports that the IL-12/IFNγ axis can antagonize Th17-induced events (24, 25), we found that IL-12 and IFNγ inhibited neutrophil migration induced by high doses of mBSA or IL-23 (Fig. 3A and B). The doses of IL-12 or IFNγ used alone were not able to induce significant neutrophil migration (data not shown). Confirming the inhibitory effect of the IL-12/IFNγ axis on IL-23/IL-17-induced neutrophil migration, we showed that anti-IFNγ antibody treatment exacerbated the neutrophil migration induced by the low dose of mBSA, an effect that was not limited by indomethacin treatment. Indomethacin treatment also did not affect the neutrophil migration induced by either the high dose of mBSA in mice treated with anti-IFNγ antibody (Fig. 3A) or the high dose of IL-23 in IL-12−/− or IFNγ−/− mice (Fig. 3C).
IL-12 inhibited IL-17 production by IL-23-stimulated peritoneal was not inhibited by indomethacin in IL-12/IFNγ axis. Neutrophils harvested from the articular cavity 24 h after intra-articular injection of mBSA (1 or 10 ng/cavity) or saline (Sal) in immunized (mBSA-im, closed bars) or mBSA (10 μg/cavity) in sham-immunized (Sham-im, open bars) mice treated with a co-injection of PGE2 (30 pg/cavity), IL-12 (10 pg/cavity), IFNγ (100 pg/cavity), or α-IFNγ antibody (700 ng/cavity). Some mice were pretreated 30 min earlier with indomethacin (Indo, 5 mg/kg, s.c.), as indicated. (B and C) Neutrophils harvested from articular cavity 6 h after intra-articular injection (1 or 10 ng/cavity) or saline (open bar) in wild-type, IL-12p40−/−, or IFNγ−/− mice. Some mice were treated with a co-injection of PGE2 (1 pg/cavity), IL-12 (0.1 ng/cavity), or IFNγ (1 ng/cavity) or were pretreated with indomethacin (Indo, 5 mg/kg, s.c. 30 min earlier). (D and E) Lymph node cells harvested from immunized mice were cultured with or without mBSA (100 μg/ml), indomethacin (Indo, 50 μg/ml), etoricoxib (Etori, 50 μg/ml), PGE2 (1 μM), α-IFNγ (10 μg/ml), or α-IL-23 (100 ng/ml) for 36 h. IL-17 and IFNγ concentrations in culture supernatants were determined by ELISA. *P < 0.05 vs. medium (RPMI) controls; #P < 0.05 vs. mBSA (10 ng/cavity) immunized, mBSA (100 μg/ml), IL-23 (10 ng/cavity) or IL-23 (100 ng/ml); &P < 0.05 vs. IL-23 (1 ng/cavity) or mBSA (1 μg/cavity) immunized. Data are mean ± SEM, n = 5, representative of at least 2 experiments.

Moreover, indomethacin, etoricoxib, and anti-IL-23 inhibited IL-17 production, whereas anti-IFNγ and PGE2 exacerbated IL-17 production. Furthermore, PGE2 inhibited the production of IFNγ by lymph node cells from immunized mice when cultured with mBSA in vitro (Fig. 3 D and E).

Extending these observations, we also demonstrated that the i.p. co-administration of low doses of IL-23 (1 ng) and PGE2−/− induced significant neutrophil migration to the peritoneal cavity compared with the injection of these mediators alone. Moreover, IL-12 inhibited the neutrophil migration induced by co-administration of PGE2 and IL-23. Furthermore, IL-12 or IFNγ inhibited the neutrophil migration induced by an effective high dose of IL-23 (Fig. S2 A4). In agreement with these observations, IL-23-stimulated neutrophil migration into the peritoneal cavity was not inhibited by indomethacin in IL-12−/− or IFNγ−/− mice (Fig. S2 B4). Finally, we showed that although indomethacin and IL-12 inhibited IL-17 production by IL-23-stimulated peritoneal cells, PGE2 enhanced IL-17 and inhibited IFNγ production (Fig. S2 C and D; see method in SI Text). Together, these results demonstrate that PGE2 potentiates IL-23-induced neutrophil migration by enhancing IL-17 production through the inhibition of the IL-12/IFNγ pathway.

IL-17-Mediated Neutrophil Migration Depends on TNFα, Leukotrienes, and CXC Chemokines. Next we addressed the mechanisms involved in IL-17-induced neutrophil migration to the articular cavity. Intra-articular injection of IL-17 induced a dose-dependent neutrophil migration peaking at 30 ng/articular cavity 6 h after IL-17 administration (Fig. 4 A). IL-17-induced neutrophil recruitment was not inhibited by indomethacin, etoricoxib, IL-12, or IFNγ treatment (Fig. S3), suggesting that PGE2, IL-12, and IFNγ regulate IL-23-induced neutrophil migration upstream of IL-17 production. However, the neutrophil migration induced by IL-17, mBSA, or IL-23 was inhibited by treatment of the mice with MK886, anti-TNFα, repertaxin (RPTX), anti-CXCL1, or anti-CXCL5 (Fig. 4). These results indicate that TNFα, leukotrienes, and CXC chemokines act downstream of IL-17 mediating mBSA-induced neutrophils.

To strengthen this conclusion further, we performed neutrophil chemotaxis in vitro. Fig. 5 shows that IL-17 induced neutrophil chemotaxis in a dose-dependent manner and was not affected by the presence of indomethacin. Furthermore, IL-17 induced chemotaxis of neutrophils from IL-12p40−/−, IFNγ−/−, or 5-LO−/− mice, and the chemotaxis also was not affected by indomethacin (Fig. 5 A). In contrast, the IL-17-induced neutrophil chemotaxis was inhibited significantly by anti-CXCR2 an-

Fig. 3. PGE2 enhances IL-23-induced neutrophil recruitment by increasing IL-17 synthesis via suppressing the IL-12/IFNγ axis. (A) Neutrophils harvested from the articular cavity 24 h after intra-articular injection of mBSA (1 or 10 μg/cavity) or saline (Sal) in immunized (mBSA-im, closed bars) or mBSA (10 μg/cavity) in sham-immunized (Sham-im, open bars) mice treated with a co-injection of PGE2 (30 pg/cavity), IL-12 (10 pg/cavity), IFNγ (100 pg/cavity), or α-IFNγ antibody (700 ng/cavity). Some mice were pretreated 30 min earlier with indomethacin (Indo, 5 mg/kg, s.c.), as indicated. (B and C) Neutrophils harvested from articular cavity 6 h after intra-articular injection of mBSA (1 or 10 ng/cavity) or saline (open bar) in wild-type, IL-12p40−/−, or IFNγ−/− mice. Some mice were treated with a co-injection of PGE2 (1 pg/cavity), IL-12 (0.1 ng/cavity), or IFNγ (1 ng/cavity) or were pretreated with indomethacin (Indo, 50 μg/ml), etoricoxib (Etori, 50 μg/ml), PGE2 (1 μM), α-IFNγ (10 μg/ml), or α-IL-23 (100 ng/ml) for 36 h. IL-17 and IFNγ concentrations in culture supernatants were determined by ELISA. *P < 0.05 vs. medium (RPMI) controls; #P < 0.05 vs. mBSA (10 ng/cavity) immunized, mBSA (100 μg/ml), IL-23 (10 ng/cavity) or IL-23 (100 ng/ml); &P < 0.05 vs. IL-23 (1 ng/cavity) or mBSA (1 μg/cavity) immunized. Data are mean ± SEM, n = 5, representative of at least 2 experiments.

Fig. 4. IL-17 mediates neutrophil migration via TNFα, leukotrienes, and CXC chemokines (CXCL1 and CXCL5). (A and C) Neutrophils harvested from articular cavity 6 h after intra-articular injection of IL-17 (1–30 ng/joint), IL-23 (10 ng/cavity), or saline (Sal, open bars) in mice treated with a co-injection of α-TNFα serum (5 μl/cavity), α-CXCL1 (700 ng/cavity), or α-CXCL5 (700 ng/cavity) antibodies. Some mice also were treated 30 min before with repertaxin (RPTX, 30 mg/kg, s.c.) or 1 h before with MK886 (1 mg/kg, by gavage). (B) Neutrophils harvested from articular cavity 24 h after intra-articular injection of mBSA (10 μg/cavity) or saline in immunized mice (mBSA-im, closed bars) or mBSA (10 μg/cavity) in sham-immunized (Sham-im, open bar) mice treated with a co-injection of IgG control (α-ctl), α-TNFα serum (5 μl/cavity), α-CXCL1 (700 ng/cavity), or α-CXCL5 (700 ng/cavity) antibodies or 1 h before with MK886 (1 mg/kg, by gavage). *P < 0.05 vs. saline control; †P < 0.05 vs. IL-23, IL-17, or mBSA (immunized) groups. Data are mean ± SEM, n = 5, representative of 3 experiments.
mediators (CXC chemokines, TNF-α) to those observed in human RA (27). Generalizing our findings, we investigated the ability of IL-23 to induce neutrophil migration into the joint cavity, which is a convenient experimental model to address the mechanisms involved in the multiple steps responsible for neutrophil migration induced by a range of stimuli (28, 29).

Prostaglandins, particularly PGE₂, as well as COX-2 and COX-1 (enzymes involved in prostaglandin synthesis) are found in the synovial tissue of RA patients and experimental models of RA (30–32). Although some in vitro studies suggest an anti-inflammatory role for PGE₂ (33), most reports implicate PGE₂ as an important pro-inflammatory agent in RA (34–36). It was previously shown that PGE₂ exacerbates CIA as a result of increased IL-23 and IL-6 expression by dendritic cells (37). We now demonstrate that locally produced COX-2-derived prostaglandins are essential for mBSA- and IL-23-induced IL-17 production and neutrophil recruitment into joints and peritoneal cavities. Inhibition of COX-2 blocked, whereas exogenous PGE₂ enhanced, mBSA- or IL-23-induced neutrophil migration. Moreover, we observed that IL-23 is able to increase COX-2 mRNA and PGE₂ production. Our results are consistent with a recent report that IL-1, a cytokine that plays a pivotal role in RA development (13, 38), is required for the synergistic effect of PGE₂ and IL-23 in promoting human Th17 expansion and the subsequent IL-17 release (39).

IL-12 and IFNγ block the polarization of Th17 cells in experimental RA (5–7, 24). Here we demonstrate that IL-12 and IFNγ inhibit neutrophil migration induced by either mBSA or IL-23 and that IL-12 limits IL-23-induced IL-17 production. Thus, it is possible that the source of IL-17 that mediates the mBSA-induced neutrophil migration is Th17 cells. However, we could not discard gamma-delta T cells, because this subset of T cells also is an important source of IL-17 and is associated with the exacerbation of CIA (40). We examined whether the effect of COX-2-derived prostaglandins in IL-23-mediated neutrophil migration is caused by the inhibition of IL-12/IFNγ production and, as a consequence, abrogation of the inhibitory effect of the IL-12/IFNγ-axis on IL-17 production. COX inhibitors were ineffective in reducing mBSA-induced neutrophil migration to the articular cavity of mice treated with anti-IFNγ antibodies. Similarly, these COX inhibitors had no effect on the IL-23-induced neutrophil migration into joints and peritoneal cavities in IL-12- or IFNγ-deficient mice. Moreover, the ability of PGE₂ to enhance IL-23-induced neutrophil migration was prevented by exogenous administration of IL-12. These results identify another experimental model to address the mechanisms involved in the multiple steps responsible for neutrophil migration induced by a range of stimuli (28, 29).

Prostaglandins, particularly PGE₂, as well as COX-2 and COX-1 (enzymes involved in prostaglandin synthesis) are found in the synovial tissue of RA patients and experimental models of RA (30–32). Although some in vitro studies suggest an anti-inflammatory role for PGE₂ (33), most reports implicate PGE₂ as an important pro-inflammatory agent in RA (34–36). It was previously shown that PGE₂ exacerbates CIA as a result of increased IL-23 and IL-6 expression by dendritic cells (37). We now demonstrate that locally produced COX-2-derived prostaglandins are essential for mBSA- and IL-23-induced IL-17 production and neutrophil recruitment into joints and peritoneal cavities. Inhibition of COX-2 blocked, whereas exogenous PGE₂ enhanced, mBSA- or IL-23-induced neutrophil migration. Moreover, we observed that IL-23 is able to increase COX-2 mRNA and PGE₂ production. Our results are consistent with a recent report that IL-1, a cytokine that plays a pivotal role in RA development (13, 38), is required for the synergistic effect of PGE₂ and IL-23 in promoting human Th17 expansion and the subsequent IL-17 release (39).

IL-12 and IFNγ block the polarization of Th17 cells in experimental RA (5–7, 24). Here we demonstrate that IL-12 and IFNγ inhibit neutrophil migration induced by either mBSA or IL-23 and that IL-12 limits IL-23-induced IL-17 production. Thus, it is possible that the source of IL-17 that mediates the mBSA-induced neutrophil migration is Th17 cells. However, we could not discard gamma-delta T cells, because this subset of T cells also is an important source of IL-17 and is associated with the exacerbation of CIA (40). We examined whether the effect of COX-2-derived prostaglandins in IL-23-mediated neutrophil migration is caused by the inhibition of IL-12/IFNγ production and, as a consequence, abrogation of the inhibitory effect of the IL-12/IFNγ-axis on IL-17 production. COX inhibitors were ineffective in reducing mBSA-induced neutrophil migration to the articular cavity of mice treated with anti-IFNγ antibodies. Similarly, these COX inhibitors had no effect on the IL-23-induced neutrophil migration into joints and peritoneal cavities in IL-12- or IFNγ-deficient mice. Moreover, the ability of PGE₂ to enhance IL-23-induced neutrophil migration was prevented by exogenous administration of IL-12. These results identify another...
important role for PGE2 in the context of RA pathogenesis as an autocrine mediator in amplifying and perpetuating chronic RA. We did not identify the PGE2 receptor that operates this PGE2 effect. However, it is possible that EP2/EP4 signaling participates, because these receptors mediate the activity of PGE2 to enhance the release IL-17 (41).

Recent studies demonstrated that IL-17 induces the release by joint structural and resident cells (e.g., chondrocytes, synovial fibroblasts, and macrophages) of several inflammatory mediators, including cytokines (e.g., TNFαs) and chemokines (e.g., CXCL1 and CXCL5), which may recruit neutrophils (42, 43). Here we identify the mediators downstream of IL-17 participating in the neutrophil migration to the joint cavities in AIA. We demonstrate that IL-17 induces a dose-dependent neutrophil migration into the tibiofemoral joints of mice. The neutrophil migration thus induced is not affected by COX inhibitors (indomethacin and etoricoxib) or by IL-12 or IFNγ. These results confirm that prostaglandin and the IL-12/IFNγ axis interferes with mBSA-induced neutrophil migration upstream of the IL-17 effect. We then demonstrate that IL-17-induced neutrophil migration to the knee joint is dependent on leukotrienes, TNFαs, CXCL1, and CXCL5.

Neutrophil migration in vitro induced by a chemotactic mediator depends mainly on the concentration gradient, whereas neutrophil migration in vivo is complex and requires, besides the concentration gradient, the activation of endothelial cells and the consequent expression of adhesion molecules (44). Therefore, neutrophil migration induced by IL-17 may not be totally via release of CXC chemokines, TNFαs, and LTB4, but also could depend on a direct effect of IL-17 on neutrophils. Here we demonstrate that IL-17 can induce neutrophil chemotaxis in vitro. However, this event is dependent on the release of CXC chemokines, suggesting that in vitro IL-17 stimulates the release of CXC chemokines by neutrophils that, acting through an autocrine manner, induce neutrophil chemotaxis.

Together, our results demonstrate that during antigen-induced neutrophil migration to the joints, IL-23 is released early and stimulates IL-17 production. IL-17 production induces the release of TNFαs, the CXC chemokines (CXCL1 and CXCL5), and LTB4, which together contribute to neutrophil recruitment by inducing locomotion and the expression of adhesion molecules (Fig. 6). IL-23 elicited during antigen challenge also can induce COX2 expression leading to the production of PGE2, which contributes to neutrophil recruitment by enhancing the production of IL-23-induced IL-17 through the impairment of the IL-12/IFNγ axis. These findings reveal a mechanism of nonsteroidal anti-inflammatory drugs used for RA treatment and suggest the possible use of such drugs in other diseases in which neutrophil migration along the IL-23/IL-17 axis is involved.

Materials and Methods

Animals and Reagents. Male and female BALB/c, C57BL/6, and 129S1/SvImJ wild types and IL-12p40 (C57BL/6)–, IFNγ (C57BL/6)–, and L–, which together contribute to neutrophil recruitment by inducing locomotion and the expression of adhesion molecules (Fig. 6). IL-23 elicited during antigen challenge also can induce COX2 expression leading to the production of PGE2, which contributes to neutrophil recruitment by enhancing the production of IL-23-induced IL-17 through the impairment of the IL-12/IFNγ axis. These findings reveal a mechanism of nonsteroidal anti-inflammatory drugs used for RA treatment and suggest the possible use of such drugs in other diseases in which neutrophil migration along the IL-23/IL-17 axis is involved.

Induction of Experimental Arthritis. BALB/c mice were sensitized (s.c.) with 500 μg of mBSA in an emulsion containing 0.1 ml PBS and 0.1 ml complete Freund’s adjuvant. Booster injections of mBSA in incomplete Freund’s adjuvant were given 7 and 14 d after the first immunization. Non-immunized (sham) mice were given similar injections but without mBSA. Arthritis was induced in the immunized mice 21 d after the initial injection by intra-articular injection of mBSA (10 μg/cavity), and the neutrophil migration was evaluated as described in the next section.

In Vivo Neutrophil Migration. Neutrophil migration was assessed 4 h after i.p. injection of IL-23 (3–30 ng/cavity) or 6 h after intra-articular injection of IL-23 (1–10 ng/cavity) and IL-17 (1–30 ng/cavity) in naive BALB/c, C57BL/6, IL-12p40–, and IFNγ–/– mice or 24 h after intra-articular mBSA challenge (1 or 10 μg/cavity) in immunized or sham-immunized BALB/c mice. These mice were treated with co-injections of 1 of the following: IL-12, IFNγ, anti-TNFαs serum, anti-IL-23, anti-IL-17, anti-IFNγ, anti-CXCL1, anti-CXCL5 30 min before injection indomethacin (a COX inhibitor, s.c.), etoricoxib (a COX-2 inhibitor, s.c.), or repertaxin (an allosteric CXCR1/2 antagonist, s.c.) or with MK886 (a 5-lipoxygenase-activating protein inhibitor, gavage) 1 h before injection. The doses used are indicated in the figure legends. At the end of the experiment, the mice were killed, and the cells present in the peritoneal or articular cavities were harvested by washing cavities with PBS/EDTA. Total and differential cell counts were performed, and the results were presented as the number (mean ± SEM) of neutrophils per cavity.

Culture of Lymph Node Cells and Neutrophils. Popliteal and inguinal lymph node cells (5 × 107 cells/well) in 250 μl of RPMI-1640 were incubated in a 96-well plates for 36 h in the presence or absence of mBSA (100 μg/ml), IL-23 (100 ng/ml), indomethacin (50 μg/ml), PGE2 (1 μM), etoricoxib (50 μg/ml), anti-IL-23 antibodies (100 ng/ml), or anti-IFNγ antibodies (10 μg/ml). The supernatants were used for detection of IL-23, IL-17, IFNγ, and PGE2 concentrations. Bone marrow neutrophils (1 × 106 cells/well), purified as described previously (45), were incubated in 250 μl of RPMI in 96-well plates for 1 h in the presence or absence of IL-17 (50 ng/ml). The CXCL1 concentrations were measured in supernatants.

Joint Homogenates. The knee joints were dissected out, frozen with liquid nitrogen, crushed in a mortar and pestle, and then solubilized in PBS. The homogenates then were centrifuged at 10,000 × g for 10 min, and the supernatants were used for detection of IL-23, IL-17, IFNγ, and CXCL1.

Measurement of IL-23, IL-17, IFNγ, CXCL1, and PGE2. IL-23, IL-17, IFNγ, and CXCL1 concentrations were assessed by ELISA using paired antibodies (detection limits, 11 pg/ml; R&D Systems). The concentrations of PGE2 were assessed by RIA (Amersham Biosciences).

RT-PCR Assays. COX-2 mRNA assay was performed by RT-PCR as previously described (29). Briefly, mice were killed 0.5, 1, 3, or 9 h after IL-23 i.p. injection, and the total peritoneal cells were harvested. Total cellular RNA from peritoneal cells was extracted using the TRIzol reagent (Gibco BRL-Life Technologies) according to the directions of the manufacturer. The primers used were COX-2 (sense: 5′-AGC CCT CTC AA9 CTC CTCA-3′; antisense: 5′-CAG CTC TCC ACC AAT GAC CT3′), and GAPDH (sense: 5′-GCC ATT AAC GAC CCC ATT G-3′; anti-sense: 5′-TGC CAG TGA GCT TCT CGT TC-3′). The expression of GAPDH mRNA was used as loading control in all samples. Densitometry analysis of scanned images was carried out using the Gel Pro-Analyzer 3.1 (MediaCybernetics) image analysis software. The integrated optical density (IOD) of the IOD of COX-2 and GAPDH.

Neutrophil Chemotaxis. Bone marrow neutrophils were purified as previously described (45), and the chemotaxis was performed using a 48-well micro chamber (Neuro Probe). The stimuli and negative control were added to the lower chambers. A 5-μm pore polycarbonate membrane (Neuro Probe) was placed between the upper and lower chambers, and 5 × 104 cells previously treated for 30 min with indomethacin (50 μg/ml) anti-CXCR2 antibodies (30 μg/ml), or repertaxin (30 μM) or not treated were added to the top chambers. Cells were allowed to migrate into the membrane for 1 h at 37 °C, 5% CO2. Following incubation, the membrane was washed in PBS, fixed in methanol, and stained using the Diff-Quik system (Dade Behring). Each well-associated membrane area was scored using light microscopy to count the intact cells present in 5 random fields. The results are expressed as the number of neutrophils per field.

Statistical Analysis. Data are presented as means ± SEM and are representative of 2 or 3 separate experiments. The means from different treatments were compared by ANOVA with Tukey’s correction. Statistical significance was set at P < 0.05.
ACKNOWLEDGMENTS. We thank Giuliana Bertozzi, Fabiola Mestriner, Ana Kátia dos Santos, Diva M. A. Souza, and Ingrid F. Metzger for their excellent technical assistance. This work was supported by grants from the Fundação de Amparo à Pesquisa do Estado de São Paulo, Pronex, Fundação de Amparo à Pesquisa do Estado de Amazonas, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior and Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brazil), The Wellcome Trust, and the Medical Research Council (United Kingdom).